What Is GHK-Cu? Benefits, Research & Safety
A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.
UK summary: Naturally occurring tripeptide-copper complex. Topical cosmetic formulations are regulated under UK cosmetics legislation; injectable forms are research-only and unlicensed. Genuine cosmetic evidence exists for topical skin and hair endpoints; injectable claims should be assessed separately.
Quick Facts
Overview
GHK-Cu — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Naturally occurring tripeptide-copper complex. Topical cosmetic formulations are regulated under UK cosmetics legislation; injectable forms are research-only and unlicensed. Genuine cosmetic evidence exists for topical skin and hair endpoints; injectable claims should be assessed separately.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Available as a cosmetic ingredient. Injectable forms not licensed for therapeutic use.
- EU: Approved cosmetic ingredient. Not authorised as a medicinal product.
- Notes: GHK-Cu is widely used in cosmetic formulations and is generally considered safe for topical use. Injectable forms remain in the research domain and are not approved for therapeutic use.
05Approved medical uses
- No UK-licensed finished medicine; topical cosmetic formulations regulated under UK cosmetics rules, not medicines law.
06Unapproved / promotional claims
- Injectable GHK-Cu reverses ageing systemically
- Heals injury and stimulates hair regrowth via injection
- Gene-expression ‘reset’ proven in humans
07Common internet claims
- Same effect topical vs injectable
- Pharma-grade copper peptide reverses biological age
- Replaces dermatologist care for skin ageing
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Topical GHK-Cu improves skin firmness and reduces wrinkles” | C | Yes | Low | Several small human trials of topical GHK-Cu show improvements in skin appearance metrics; effect sizes vary by formulation. |
| “Injectable GHK-Cu regenerates tissue and reverses ageing” | D | No | High | Mechanistic and animal-model evidence; human injectable evidence is limited and unlicensed in the UK. |
| “Reverses hair loss” | C | Limited | Moderate | Some topical hair-growth studies are encouraging; effect size is modest and the formulation matters. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Topical: mild irritation in sensitive individuals (uncommon).
- Injectable: limited UK safety data; sterility risk from grey-market vials.
- Copper-overload theoretical risk with long-term systemic use.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Available as a cosmetic ingredient. Injectable forms not licensed for therapeutic use.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Approved cosmetic ingredient. Not authorised as a medicinal product.
15What this page cannot tell you
- Whether topical or injectable is appropriate for your skin or condition.
- Whether an injectable vial purchased online contains what it claims.
- Long-term safety of injectable GHK-Cu (largely uncharacterised).
- How injectable use interacts with other medicines or skin conditions.
16Last reviewed
17Citation quality score
18Research gaps
- No large human RCTs of injectable GHK-Cu for any indication.
- Comparative efficacy of injectable vs topical not characterised in humans.
- Long-term safety of systemic copper-peptide exposure.
19Safer alternatives / established care pathways
- Clinically-validated topical cosmetic formulations.
- Dermatologist-led plans for skin ageing or hair-loss concerns.
- Licensed treatments for specific dermatology indications (e.g. minoxidil, retinoids).
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is the form I'm asking about topical (cosmetic) or injectable (unlicensed research)?
- What does the human evidence actually support for the indication I have?
- Are there licensed UK alternatives for my dermatology concern?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Accelerated wound healing with improved tissue quality in multiple studies
- 2Increased collagen and elastin synthesis for improved skin structure
- 3Enhanced skin elasticity, firmness, and thickness
- 4Reduced appearance of fine lines and wrinkles in clinical studies
- 5Potential hair growth stimulation and follicle support
- 6Anti-inflammatory effects that may benefit various conditions
- 7Antioxidant activity protecting tissues from oxidative damage
- 8Possible neuroprotective effects under investigation
Claim vs Evidence
How popular claims about GHK-Cu stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Topical GHK-Cu improves skin firmness and reduces wrinkles” | C | Yes | Low | Several small human trials of topical GHK-Cu show improvements in skin appearance metrics; effect sizes vary by formulation. |
| “Injectable GHK-Cu regenerates tissue and reverses ageing” | D | No | High | Mechanistic and animal-model evidence; human injectable evidence is limited and unlicensed in the UK. |
| “Reverses hair loss” | C | Limited | Moderate | Some topical hair-growth studies are encouraging; effect size is modest and the formulation matters. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Topical: 1-3% in formulations; Injectable: highly variable in research settings |
| Frequency | Topical applications typically once or twice daily |
| Duration | Variable depending on application; skin improvements often observed over 8-12 weeks |
| Notes | Topical GHK-Cu is widely available in commercial skincare products. Injectable forms remain primarily in research settings. The optimal delivery system and concentration may vary by application. Consult a dermatologist for personalised skincare recommendations. |
Administration Routes
Routes studied in research settings (educational only):
- Topical application (most common, available in commercial products)
- Subcutaneous injection (research settings)
- Intradermal injection (research settings)
| Half-Life | Stability |
|---|---|
| Variable depending on formulation; plasma half-life of unbound GHK-Cu is relatively short | Stable in appropriate formulations; copper peptide complexes can be sensitive to certain conditions |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Mild skin irritation with topical application in some individuals
- Temporary redness at application site
- Possible allergic reactions in sensitive individuals
Rare Risks & Concerns
- Allergic reactions to copper or peptide components
- Theoretical concerns regarding copper accumulation with excessive use
- Unknown long-term effects of injectable forms in humans
Contraindications
- Known allergy to copper or peptide components
- Wilson's disease (impaired copper metabolism)
- Pregnancy and breastfeeding (precautionary)
- Active skin infections at application site
UK & EU Regulatory Context
🇬🇧 United Kingdom
Available as a cosmetic ingredient. Injectable forms not licensed for therapeutic use.
🇪🇺 European Union
Approved cosmetic ingredient. Not authorised as a medicinal product.
Clinical Studies Summary
The Human Tripeptide GHK-Cu in the Prevention of Oxidative Stress and Degenerative Conditions
Review of GHK-Cu's antioxidant properties and potential applications in age-related conditions.
Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.
Copper tripeptide complex (GHK-Cu) skin care products placed on CO(2) laser-resurfaced skin offered no significant reduction or resolution of posttreatment erythema. Objective evaluation found no significant improvement in wrinkles or overall skin quality. However, patient satisfaction was significantly higher for those who used GHK-Cu skin care products after CO(2) laser skin resurfacing.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown.
Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?
An analysis of the literature data reveals that the transport of liposomes containing GHK-Cu received little attention. This research gap gives an impetus to the methodological developments for assessing the effect of liposomes on GHK-Cu transportation and trafficking.
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.
GHK has also been found to possess powerful cell protective actions, such as multiple anti-cancer activities and anti-inflammatory actions, lung protection and restoration of chronic obstructive pulmonary disease (COPD) fibroblasts, suppression of molecules thought to accelerate the diseases of aging such as NFκB, anti-anxiety, anti-pain and anti-aggression activities, DNA repair, and activation of cell cleansing via…
The human tri-peptide GHK and tissue remodeling.
GHK-Cu also improves hair transplant success, protects hepatic tissue from tetrachloromethane poisoning, blocks stomach ulcer development, and heals intestinal ulcers and bone tissue. These results are beginning to define the complex biochemical processes that regulate tissue remodeling.
Registered Trials & Regulatory Status
Topical GHK-Cu Gel for Acute Skin Wound Healing
Status: Recruiting · 60 participants · Hudson Biotech
Conditions: Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for GHK-Cu?
Source research-grade GHK-Cu from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about GHK-Cu
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is the form I'm asking about topical (cosmetic) or injectable (unlicensed research)?
- What does the human evidence actually support for the indication I have?
- Are there licensed UK alternatives for my dermatology concern?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Combination Protocols
Related Peptides
BPC-157
A pentadecapeptide derived from human gastric juice, extensively researched for its potential tissue repair and regenerative properties across multiple organ systems.
Learn moreTB-500
A synthetic version of the naturally occurring peptide Thymosin Beta-4, extensively researched for its roles in tissue repair, cell migration, and angiogenesis.
Learn moreMatrixyl
A pioneering signal peptide that mimics natural collagen-boosting messengers, extensively validated in clinical studies for wrinkle reduction and skin firmness improvement.
Learn moreArgireline
A neuromodulating hexapeptide that reduces facial muscle contractions through SNARE complex inhibition, providing a topical alternative to botulinum toxin for expression line reduction.
Learn moreSyn-Ake
A tripeptide that mimics the neuromuscular blocking effects of Temple Viper venom (waglerin-1), targeting nicotinic acetylcholine receptors to reduce expression lines.
Learn moreEpitalon
A synthetic tetrapeptide based on epithalamin, researched for its potential effects on telomerase activation and biological ageing.
Learn more